{"id":7684,"date":"2005-01-31T08:15:28","date_gmt":"2005-01-31T07:15:28","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=7684"},"modified":"2014-05-22T15:14:11","modified_gmt":"2014-05-22T15:14:11","slug":"44th-interscience-conference-on-antimicrobial-agents-and-chemotherapy-icaac-30-october-2-november-2004-washington","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/7684","title":{"rendered":"44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 30 October-2 November 2004, Washington"},"content":{"rendered":"<p><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong><a href=\"https:\/\/i-base.info\/htb\/keyword\/icaac-44th-2004\">Report from the conference<\/a><\/strong>.<\/p>\n<ul>\n<li><a title=\"Permanent link to Tipranavir in treatment experienced patients: results from RESIST-1\" href=\"https:\/\/i-base.info\/htb\/7680\" rel=\"bookmark\">Tipranavir in treatment experienced patients: results from RESIST-1<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Reverset: first data in patients with nucleoside resistance\" href=\"https:\/\/i-base.info\/htb\/7678\" rel=\"bookmark\">Reverset: first data in patients with nucleoside resistance<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Poor response with tenofovir and ddI backbone causes early study termination\" href=\"https:\/\/i-base.info\/htb\/7675\" rel=\"bookmark\">Poor response with tenofovir and ddI backbone causes early study termination<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Paradoxical CD4 response with tenofovir and ddI backbone\" href=\"https:\/\/i-base.info\/htb\/7670\" rel=\"bookmark\">Paradoxical CD4 response with tenofovir and ddI backbone<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Tenofovir\/FTC backbone outperforms AZT\/3TC (Combivir) with efavirenz in treatment naive patients; reduced toxicity drives ITT viral efficacy\" href=\"https:\/\/i-base.info\/htb\/7665\" rel=\"bookmark\">Tenofovir\/FTC backbone outperforms AZT\/3TC (Combivir) with efavirenz in treatment naive patients; reduced toxicity drives ITT viral efficacy<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Limited stability of lopinavir\/r (Kaletra) above 25\u00b0C\" href=\"https:\/\/i-base.info\/htb\/7662\" rel=\"bookmark\">Limited stability of lopinavir\/r (Kaletra) above 25\u00b0C<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Atorvastatin requires dose reduction with tipranavir\/r\" href=\"https:\/\/i-base.info\/htb\/7660\" rel=\"bookmark\">Atorvastatin requires dose reduction with tipranavir\/r<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Once-daily T-20 is less effective than twice daily: lower potency is related to C trough\" href=\"https:\/\/i-base.info\/htb\/7658\" rel=\"bookmark\">Once-daily T-20 is less effective than twice daily: lower potency is related to C trough<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Further genetic link to efavirenz absorption\" href=\"https:\/\/i-base.info\/htb\/7656\" rel=\"bookmark\">Further genetic link to efavirenz absorption<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Long-term response to FTC in children is similar to adults\" href=\"https:\/\/i-base.info\/htb\/7654\" rel=\"bookmark\">Long-term response to FTC in children is similar to adults<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Side effects update: hypersensitivity, heart, bones\" href=\"https:\/\/i-base.info\/htb\/7652\" rel=\"bookmark\">Side effects update: hypersensitivity, heart, bones<\/a><\/li>\n<\/ul>\n<p>Over the last few years the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) has had a reduced focus on HIV. This years meeting however included several important oral presentations and posters of interest.<\/p>\n<p>ICAAC still maintains a restricted approach to making the research presented at these annual meetings available publicly. Although the website currently includes searchable abstracts, webcasts of many oral sessions, and the slides from some of these presentations, this is only for one month after the conference. The meeting is then available on CD Rom for around $300, but the public access stops. Notably, this conference still refuses to allow these abstract to join the online resource developed by AEGiS.org.<\/p>\n<p>Unfortunately, abstracts that are currently available on the conference website are linked to pop-up windows, and this means that we are not able to provide direct weblinks for referenced articles in the way HTB does for routine conference coverage.<\/p>\n<p>Abstracts can nevertheless be\u00a0browsed and searched from this web address:<\/p>\n<p><a href=\"http:\/\/www.abstractsonline.com\/viewer\/browseOptions.asp?MKey={CE64B3B3-6CEB-40D2-ACDF- 14A2BE602044}&amp;AKey={32093528-52DC-4EBE-9D80-29DAD84C92CE}\">www.abstractsonline.com\/viewer\/browseOptions.asp?MKey={CE64B3B3-6CEB-40D2-ACDF-<br \/>\n14A2BE602044}&amp;AKey={32093528-52DC-4EBE-9D80-29DAD84C92CE}<\/a><\/p>\n<p>Conference coverage also provided by the following sites:<\/p>\n<ul>\n<li><a href=\"http:\/\/www.thebody.com\/confs\/icaac2004\/complete.shtml\">www.thebody.com\/confs\/icaac2004\/complete.shtml<\/a><\/li>\n<li><a href=\"http:\/\/www.natap.org\">www.natap.org<\/a><\/li>\n<\/ul>\n<p>Abstract summaries organised by subject are provided by:<\/p>\n<ul>\n<li><a href=\"http:\/\/www.hivandhepatitis.com\/2004icr\/icaac2004\/main.html\">www.hivandhepatitis.com\/2004icr\/icaac2004\/main.html<\/a><\/li>\n<li><a href=\"http:\/\/clinicaloptions.com\/hiv\/conf\/icaac2004\">clinicaloptions.com\/hiv\/conf\/icaac2004<\/a><\/li>\n<\/ul>\n<p>Unless otherwise stated, all references are to the Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 30 October \u2013 2 November 2004, Washington, DC.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base Report from the conference. Tipranavir in treatment experienced patients: results from RESIST-1 Reverset: first data in patients with nucleoside resistance Poor response with tenofovir and ddI backbone causes early study termination Paradoxical CD4 response with tenofovir &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[12,99],"class_list":["post-7684","post","type-post","status-publish","format-standard","hentry","category-conference-reports","tag-conference-index","tag-icaac-44th-2004"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/7684","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=7684"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/7684\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=7684"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=7684"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=7684"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}